Work

Appropriate delay of primary tumour radiotherapy may lead to better long-term overall survival for non-small cell lung cancer treated with EGFR-TKIs

Year: 2024

Type: article

Abstract: The most appropriate time of primary tumor radiotherapy in non-small cell lung cancer(NSCLC) with EGFR-TKIs remains unclear. The aim of this study was to investigate the effect of the time factor of primary tumor radiotherapy on long-term overall survival(OS)and provide a theoretical basis for further clinical research. In total, 238 patients with EGFR-TKIs and OS ≥ 12 months were statistically analysed. Patients were grouped: the D group without primary tumor radiotherapy and the R group with it.The R group were divided into three groups according to the interval between the start of EGFR-TKIs and the start of primary tumor radiotherapy: R 0 − 30 (<30 days), R 30 − PD (≥ 30 days and disease stable), and R PD (radiotherapy after disease progression). The Kaplan-Meier method and log-rank test were used for survival analyses. Exploratory landmark analyses were investigated. The OS rates at 1, 2, 3, 5 years for the R group and D group were 96.8%, 62.9%, 38.3%, 17.1%, and 95.6%, 37.7%, 21.8%, 2.9%, respectively; the corresponding MST was 29 months(95% CI: 24.3–33.7) for the R group and 22 months(95% CI: 20.4–23.6) for the D group (χ 2 = 13.480, p <0.001). Multivariate analysis revealed that primary tumor radiotherapy was independent predictors of prolonged OS.Among the four groups, The R 30 − PD appeared to have the best OS (D, χ 2 = 19.307, p <0.001;R 0 − 30 , χ 2 = 11.687, p = 0.01; R PD , χ 2 = 4.086, p = 0.043). Landmark analyses(22 months) showed the R 30 − PD group had a significant long-term OS.The incidence of radiation pneumonitis ≥ grade 2 was17.3%( n = 19)and radiation esophagitis ≥ grade 2 was observed in 32 patients(29.1%). Our results showed that primary tumour radiotherapy may prolong long-term OS with acceptable toxicities. Appropriate delay(R 30 − PD )of primary tumour radiotherapy may be the best choice.Premature radiotherapy(R 0 − 30 ) and radiotherapy after disease progression (R PD )may not be reasonable for long-term OS.

Source: BMC Cancer

DOI: 10.1186/s12885-024-12826-1